American heart journal plus : cardiology research and practice最新文献

{"title":"Phase-dependent iron dysmetabolism in myocardial ischemia-reperfusion injury: From mechanisms to therapies","authors":"Yilin Huang ,&nbsp;Shuang Li ,&nbsp;Yuanlin Zeng ,&nbsp;Zeyu Zhang","doi":"10.1016/j.ahjo.2025.100653","DOIUrl":"10.1016/j.ahjo.2025.100653","url":null,"abstract":"<div><div>Myocardial ischemia-reperfusion injury (MIRI) remains a critical clinical challenge, often worsening myocardial damage after reperfusion therapy for acute myocardial infarction (AMI). Phase-dependent dysregulation of iron homeostasis is critically involved in the pathogenesis of MIRI. Ischemia leads to depletion of the labile iron pool (LIP) and iron accumulation in cardiomyocytes, whereas reperfusion leads to iron overload and oxidative stress. These changes destroy cellular homeostasis, triggering ferroptosis and other programmed cell death pathways. Potential therapeutic targets have been identified through molecular mechanisms regulating ferritinophagy, hepcidin modulation, and transferrin receptor 1-mediated iron transport. This review summarizes research progress in these phase-specific changes in iron metabolism during myocardial ischemia and reperfusion, emphasizing their roles in oxidative stress and cell damage. Potential therapeutic strategies integrate the correction of dysregulated homeostasis into clinical trials using drugs that target AMI and MIRI, offering perspectives for the development of novel treatments.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100653"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145419188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter by Zhang regarding article, “supersaturated oxygen therapy using radial artery access to prevent left ventricular remodeling after anterior ST-segment elevation myocardial infarction: A randomized, controlled trial”","authors":"Zonglei Zhang","doi":"10.1016/j.ahjo.2025.100641","DOIUrl":"10.1016/j.ahjo.2025.100641","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100641"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145323665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter 2 inhibitors for wild-type transthyretin amyloidosis: Insights from a global database","authors":"Z. Zathar ,&nbsp;D.G. Wilson","doi":"10.1016/j.ahjo.2025.100625","DOIUrl":"10.1016/j.ahjo.2025.100625","url":null,"abstract":"<div><h3>Background</h3><div>Wild-type transthyretin amyloidosis (wtATTR) is an increasingly recognised cause of infiltrative cardiomyopathy, particularly in the elderly population. The use of traditional heart failure prognostic therapies in this group may be limited by age-associated comorbidities and heightened vulnerability to changes in renal function and blood pressure. We aimed to assess the potential prognostic impact of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in wtATTR.</div></div><div><h3>Methods</h3><div>Using data from a federated global electronic medical record database (TriNetX), patients diagnosed with wtATTR between 2005 and 2025 were identified and followed for up to 5 years. Patients were stratified into two groups based on SGLT2i use with 1:1 propensity score matching (PSM) between the cohorts. The primary outcome was all-cause mortality, and secondary outcome was clinical decompensation for heart failure.</div></div><div><h3>Results</h3><div>A total of 1,160 patients treated with SGLT2i and 2,325 patients without SGLT2i met inclusion criteria for the study. After PSM, each group contained 909 patients with comparable covariates. Mean age was 77.3±9.2 years (81.4% male) in the treatment group and 77.9±7.5 years (82.5% male) for control. Median follow-up was 297 days in the treatment group and 438 days in the control group. Patients treated with SGLT2i had lower all-cause mortality (hazard ratio [HR] 0.62; 95% CI 0.49-0.79) and clinical decompensation for heart failure (odds ratio [OR] 0.61; 95% CI 0.40-0.94).</div></div><div><h3>Conclusion</h3><div>SGLT2i use was associated with better survival and a lower incidence of clinical heart failure. These findings signal a potential prognostic benefit of SGLT2i in wtATTR that should be explored further.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100625"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145365142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of all-cause and cause-specific mortality after myocardial infarction – a Hungarian registry study","authors":"Tamás Ferenci ,&nbsp;András Jánosi","doi":"10.1016/j.ahjo.2025.100663","DOIUrl":"10.1016/j.ahjo.2025.100663","url":null,"abstract":"<div><h3>Study Objective</h3><div>Despite advances, myocardial infarction remains a significant public health concern, with survival being a crucial outcome measure. While all-cause mortality is well-studied, less is known about causes of death following an infarction. This study aimed to analyse cause-specific mortality after myocardial infarction and to compare it with the analysis of all-cause mortality.</div></div><div><h3>Design</h3><div>Data from a nationwide Hungarian myocardial infarction registry from January 2020 to June 2022 were linked with official cause of death information. Cumulative incidence functions and multivariable modelling of subdistribution hazard were used for cause-specific survival analysis, accounting for competing risks. Standard all-cause survival analysis (Cox proportional hazards model) was also carried out as a comparison.</div></div><div><h3>Results</h3><div>Among 27,965 patients with acute myocardial infarction, 25.0 % died during follow-up (of a median of 661 days). Myocardial infarction was the primary cause of death in 38.6 % of cases, followed by other cardiovascular causes (37.5 %). Factors associated with higher cause-specific mortality for infarction included older age, male sex, ST-elevation infarction, diabetes, prior stroke, peripheral artery disease, and heart failure. Percutaneous coronary intervention and hypertension was associated with lower hazard. Results largely matched all-cause survival analysis, except for ST-elevation, where hazard was much higher in cause-specific analysis.</div></div><div><h3>Conclusions</h3><div>While overall and cause-specific analyses aligned in this large registry study, a notable difference was observed for ST-elevation infarction, where hazard was substantially higher in the cause-specific analysis. This highlights the potential relevance of distinguishing between causes of death for a more precise understanding of outcomes.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100663"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145467525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence enhanced contemporary pulmonary hypertension care","authors":"Pyi Naing ,&nbsp;Gregory M. Scalia ,&nbsp;Dale Murdoch ,&nbsp;Isuru Ranasinghe ,&nbsp;Doug L. Forrester ,&nbsp;Geoff Strange ,&nbsp;David Playford","doi":"10.1016/j.ahjo.2025.100673","DOIUrl":"10.1016/j.ahjo.2025.100673","url":null,"abstract":"<div><div>All-cause pulmonary hypertension (PH) is associated with increased mortality and an enormous public health concern. However, given its complexity, multiple potential etiologies and inherent diagnostic challenges, PH diagnosis may be delayed or missed entirely. Artificial Intelligence (AI) shows potential to provide a simple but multifaceted, personalized approach for early identification of PH. AI-assisted patient triage may help highlight individuals requiring further investigation. Echocardiography may improve the identification of PH due to left heart disease and PH from other causes using a combination of AI systems such as image guidance, auto-measurement, deep phenotyping and smart reporting. Multi-level AI integrating clinical and echocardiographic data has the potential to democratize access to medical care and assist in selecting those most at risk for thorough evaluation at expert centers. In this state-of-the-art review, we discuss how new technology including AI can assist in improving the diagnosis and management of PH.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100673"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New recommendations for rhythm control—What has changed in the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for atrial fibrillation, and where does dronedarone fit in?","authors":"Gerald V. Naccarelli ,&nbsp;Justin Rackley ,&nbsp;Giuseppe Boriani","doi":"10.1016/j.ahjo.2025.100645","DOIUrl":"10.1016/j.ahjo.2025.100645","url":null,"abstract":"<div><div>In recent years, the importance of early rhythm control to delay the progression of atrial fibrillation (AF) has been recognized, as have the benefits of catheter ablation and antiarrhythmic drugs (AADs) as first-line therapy for rhythm control. Selecting the most appropriate AAD according to its safety profile as well as individual patient characteristics is of key importance. To inform decision-making, up-to-date guidelines are paramount. The American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Clinical Pharmacy (ACCP)/Heart Rhythm Society (HRS) guidelines for AF were updated in 2023, while the European Society of Cardiology (ESC) guidelines for AF were updated in 2024.</div><div>Dronedarone is an AAD indicated in the US to reduce the risk of hospitalization for AF in patients in sinus rhythm with a history of paroxysmal or persistent AF. In Europe, it is indicated for the maintenance of sinus rhythm after successful cardioversion in clinically stable adults with paroxysmal or persistent AF. Since the last major review of the efficacy and safety of dronedarone (published in 2019), multiple real-world evidence (RWE) studies and post hoc analyses of key dronedarone randomized controlled trials have been performed. This review discusses the findings of these RWE studies and post hoc analyses in the context of the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for AF with a focus on dronedarone as a treatment option for early rhythm control, its use after catheter ablation, and its use in people with heart failure and a mildly reduced or preserved ejection fraction.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100645"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145618191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine and cardiovascular outcomes in MINOCA: A retrospective cohort study","authors":"Peter Oro ,&nbsp;Aravinthan Vignarajah ,&nbsp;Joseph El Dahdah ,&nbsp;Nishanthi Vigneswaramoorthy ,&nbsp;Yousif Awakeem ,&nbsp;Gautam V. Shah","doi":"10.1016/j.ahjo.2025.100643","DOIUrl":"10.1016/j.ahjo.2025.100643","url":null,"abstract":"<div><h3>Background</h3><div>MINOCA accounts for 5 %–15 % of myocardial infarctions and is defined by &lt;50 % coronary stenosis without an alternative diagnosis, with heterogeneous mechanisms that complicate care. Given the role of inflammation and microvascular dysfunction, we evaluated whether colchicine improves outcomes.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using TriNetX, a federated health research network of 134 million patients from 102 healthcare organizations. Adults (≥18 years) with a primary diagnosis of acute myocardial infarction (AMI) and no revascularization after cardiac catheterization and without alternative diagnosis of elevated troponin were classified as MINOCA according to AHA criteria. Patients with MINOCA on colchicine (≥1 year of use for any indication) were propensity score matched with patients who were not on colchicine.</div></div><div><h3>Results</h3><div>The primary composite outcome defined as AMI recurrence, all-cause mortality, cerebrovascular events, and all-cause hospitalizations, was significantly lower with colchicine (HR 0.839, 95 % CI 0.750–0.938, <em>p</em> &lt; 0.001). Secondary outcomes of AMI recurrence (HR 0.749, 95 % CI 0.646–0.867, <em>p</em> &lt; 0.001) and all-cause mortality (HR 0.518, 95 % CI 0.312–0.862, p &lt; 0.001) were significantly lower in the colchicine group. Heart failure events (HR 0.861, 95 % CI 0.723–1.026, <em>p</em> &gt; 0.05) and all-cause hospitalizations (HR 0.892, 95 % CI 0.779–1.020, <em>p</em> = 0.764) showed a trend toward lower rates with colchicine, which was not statistically significant. There was no difference in cerebrovascular events between the two groups (HR 1.364, 95 % CI 0.638–2.914, <em>p</em> = 0.820).</div></div><div><h3>Conclusions</h3><div>In this large real-world cohort, there was a trend toward reduced cardiovascular outcomes in patients with MINOCA who were on colchicine. These findings support further prospective evaluation of colchicine in this understudied population.</div></div><div><h3>Meeting presentation</h3><div>A portion of this work was presented as a poster at the 2025 American College of Cardiology Annual Scientific Session (Abstract #1047–113) on March 29, 2025, but the full manuscript and supplementary material remain unpublished. All authors have reviewed and approved the submission and report no conflicts of interest.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100643"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145324649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Alzheimer's disease and heart failure-related mortality among older American adults: Insights from the CDC WONDER database","authors":"Yasmeen Shaikh ,&nbsp;Syeda Shahnoor ,&nbsp;Muhammad Ahmed Ali Fahim ,&nbsp;Abdul Moiz Khan ,&nbsp;Tasleem Shaikh ,&nbsp;Abdul Moeed ,&nbsp;Muhammad Sohaib Asghar","doi":"10.1016/j.ahjo.2025.100677","DOIUrl":"10.1016/j.ahjo.2025.100677","url":null,"abstract":"<div><h3>Introduction</h3><div>Alzheimer's disease is one of the leading causes of death among the elderly in the United States with heart failure sharing similar risk factors. This study investigated trends and disparities in Alzheimer's disease mortality among older adults with heart failure from 1999 to 2020 in the United States.</div></div><div><h3>Methods</h3><div>Making use of ICD-10 codes death certificate data from the Centers for Disease Control and Prevention Wide-Ranging OnLine Data for Epidemiologic Research database was retrieved for patients aged ≥65 years between 1999 and 2020. Age-adjusted mortality rates (AAMRs), per 100,000 people, and Annual Percentage Change (APCs) with their respective 95 % Confidence Intervals (CI) were also calculated. Data was stratified by year, gender, race and geographical distribution.</div></div><div><h3>Results</h3><div>Alzheimer's disease with coexisting heart failure was responsible for 192,459 deaths between 1999 and 2020. Overall the AAMR increased from 21.32 in 1999 to 24.56 in 2005 (APC: 1.9760*; 95 % CI: 0.6001 to 3.9507) after which a significant decrease to 16.52 by 2013 was observed (APC: −4.9301*; 95 % CI: −6.5209 to −4.0119). AAMRs decreased from this point forward reaching 22.21 in 2020 (APC: 4.1573*; 95 % CI: 3.0373 to 5.7232). Women had higher AAMRs than men (21.57 vs 18.41). Among racial groups, the Non-Hispanic (NH) White (21.62) population had the highest AAMRs followed by NH Black/African American (17.87), Hispanic/Latino (14.3) and NH Asian/Pacific Islander (8.96). Furthermore, AAMRs also varied by census region (West: 24.05; Midwest: 22.83; South: 21.1; Northeast: 13.38). Moreover, nonmetropolitan areas had higher AAMRs compared to metropolitan areas (27.23 vs 19.09). States in the top 90th percentile such as Kentucky, Oklahoma, Washington, North Dakota and Mississippi had AAMRs that were three times higher relative to states in the lower 10th percentile including Nevada, Florida, New York, District of Columbia and Hawaii.</div></div><div><h3>Conclusion</h3><div>Alzheimer's disease mortality with associated heart failure has shown considerable variation in adults ≥65 years. AAMRs were highest in women, NH Whites, residents of the West and nonmetropolitan patient populations. Targeted interventions and a more holistic approach to patient management are essential in achieving favorable outcomes for vulnerable groups moving forward.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100677"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sustained adherence to guideline-directed medical therapy on clinical outcomes in older adults with new-onset heart failure with reduced ejection fraction","authors":"Xichong Liu ,&nbsp;Chan Hee J. Choi ,&nbsp;C. William Pike ,&nbsp;Gavin Hui ,&nbsp;Jananee Muralidharan ,&nbsp;Shriram Nallamshetty","doi":"10.1016/j.ahjo.2025.100670","DOIUrl":"10.1016/j.ahjo.2025.100670","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100670"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating mitochondrial cell-free DNA levels are associated with the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation","authors":"Tomoko Takahashi ,&nbsp;Takeshi Soeki ,&nbsp;Kazuki Tezuka ,&nbsp;Tomomi Matsuura ,&nbsp;Etsuko Uematsu ,&nbsp;Hiroyuki Aibara ,&nbsp;Ryou Bando ,&nbsp;Robert Zheng ,&nbsp;Tomonori Takahashi ,&nbsp;Yoshihito Saijo ,&nbsp;Yutaka Kawabata ,&nbsp;Muneyuki Kadota ,&nbsp;Tomoya Hara ,&nbsp;Rie Ueno ,&nbsp;Takayuki Ise ,&nbsp;Koji Yamaguchi ,&nbsp;Shusuke Yagi ,&nbsp;Hirotsugu Yamada ,&nbsp;Daiju Fukuda ,&nbsp;Masataka Sata","doi":"10.1016/j.ahjo.2025.100638","DOIUrl":"10.1016/j.ahjo.2025.100638","url":null,"abstract":"<div><h3>Background</h3><div>Although catheter ablation, including pulmonary vein isolation, is the primary nonpharmacological therapy for atrial fibrillation (AF), atrial arrhythmia often recurs. Recent studies have linked circulating mitochondrial cell-free DNA (mt-cfDNA), a potential contributor to inflammatory disorders, with AF. In this study, we evaluated the relationship between plasma mt-cfDNA levels and AF recurrence after catheter ablation in patients with AF.</div></div><div><h3>Methods</h3><div>Peripheral blood was obtained from 58 patients with AF (34 paroxysmal and 24 persistent AF) who underwent catheter ablation and from the control group (10 patients without AF). We extracted total cfDNA and mt-cfDNA from the patients.</div></div><div><h3>Results</h3><div>The total cfDNA concentration and copy number of mt-cfDNA were significantly higher in patients with AF than in controls. During the 16-month follow-up after catheter ablation, AF recurred in 11 patients (19.0 %). In patients with AF, the copy number of mt-cfDNA before catheter ablation was higher in the recurrent group than in the non-recurrent group. However, total cfDNA concentrations did not differ significantly between patients with and without AF recurrence. The left atrial volume index (LAVI) was higher in patients with recurrent AF than in those without. Cox proportional hazards regression analysis showed that the mt-cfDNA copy number was significantly associated with AF recurrence after catheter ablation, independent of age, sex, body mass index, LAVI, and AF type.</div></div><div><h3>Conclusion</h3><div>Elevated mt-cfDNA levels may be a sensitive predictor of AF recurrence after catheter ablation in patients with AF.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"60 ","pages":"Article 100638"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145365216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}